Emerging treatments for ulcerative colitis: a systematic review

@article{Kokkinidis2017EmergingTF,
  title={Emerging treatments for ulcerative colitis: a systematic review},
  author={Damianos G. Kokkinidis and Eftychia E Bosdelekidou and Sotiria Maria Iliopoulou and A. Tassos and Pavlos Texakalidis and Konstantinos P. Economopoulos and Antonis A Kousoulis},
  journal={Scandinavian Journal of Gastroenterology},
  year={2017},
  volume={52},
  pages={923 - 931}
}
Abstract Objectives: Various investigational medicinal products have been developed for ulcerative colitis (UC). Our aim was to systematically evaluate novel pharmacological therapeutic agents for the treatment of UC. Material and methods: Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) recommendations were followed. A search of the medical literature was conducted in the MEDLINE database for original research papers published between 01 January 2010 and 31 October… Expand
Positioning therapies in ulcerative colitis.
TLDR
A review of the literature is conducted to provide an up-to-date overview of the available evidence on this topic and suggest the optimal position of therapies in these algorithms remains unclear. Expand
ASSESMENT OF QUALITY OF LIFE IN PATIENTS WITH ULCERATIVE COLITIS
TLDR
The hypothesis that patients with ulcerative colitis have reduced quality of life when compared to healthy individuals is confirmed. Expand
The onset of ulcerative colitis upon Helicobacter pylori eradication in a 72-year-old woman: report of a rare case with a 3-year follow-up
TLDR
The case of a 72-year-old female with an elderly-onset UC developed upon H. pylori eradication provides a unique clinical context for a growing body of literature suggesting molecular mechanisms involved in the interaction of genes, environment, and microbiota to be of critical importance in the etiopathogenesis of UC. Expand
Proteomics and Lipidomics in Inflammatory Bowel Disease Research: From Mechanistic Insights to Biomarker Identification
TLDR
This review focuses on the rapidly evolving proteomics and lipidomics technologies and their broad applicability to IBD studies; these range from investigations of immune-regulatory mechanisms and biomarker discovery to studies dissecting host–microbiome interactions and the role of intestinal epithelial cells. Expand
[Gastrointestinal tract diseases induced by medications].
Gastrointestinal symptoms are common side effects of medical drugs. They are usually mild but sometimes require diagnostic endoscopy and histologic evaluation. Due to the rapidly increasing number ofExpand
Contemporary Medical Management of Acute Severe Ulcerative Colitis.
TLDR
Important concepts and recent advances in the evaluation and medical management of adult and pediatric patients with acute severe ulcerative colitis are reviewed. Expand
Periplaneta americana extract promotes intestinal mucosa repair of ulcerative colitis in rat 1
TLDR
PA treatment had a significant healing effect on the OXZ-colitis model and significantly reduced the lesioned area, especially in the PA-40H groups, suggesting that Periplaneta americana extract may be a potential compound for the treatment of colonic lesions. Expand
Anti-Inflammatory and Antioxidant Activities of the Methanolic Extract of Cyrtocarpa procera Bark Reduces the Severity of Ulcerative Colitis in a Chemically Induced Colitis Model
TLDR
The C. procera methanolic extract displayed good antioxidant capacity, probably due to the presence of polyphenolic compounds, in particular the flavonoids that were identified, such as chrysin, naringenin, kaempferol, and catechin, which have been reported to have anti-inflammatory and antioxidant activities. Expand
Traditional Bulgarian Dairy Products: Ethnic Foods with Health Benefits
TLDR
This review emphasises the features of LAB starters and the autochthonous microflora, the biochemistry of dairy food production, and the approaches for achieving the fortification of the foods with prebiotics, bioactive peptides, and other metabolites with reported beneficial effects on human health. Expand
Erkrankungen des Gastrointestinaltrakts unter medikamentöser Immunmodulation
ZusammenfassungNebenwirkungen von Medikamenten im Gastrointestinaltrakt sind zwar häufig, jedoch meist passager und wenig gefährdend. Bei nur wenigen schwerwiegenderen Verläufen wird eine EndoskopieExpand
...
1
2
...

References

SHOWING 1-10 OF 44 REFERENCES
Vedolizumab for the Treatment of Active Ulcerative Colitis: A Randomized Controlled Phase 2 Dose‐ranging Study
TLDR
Vedolizumab demonstrated dose‐proportional pharmacokinetics and maximally saturated receptors on peripheral serum lymphocytes at all measurable serum concentrations over the tested dose range. Expand
Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis.
TLDR
Golimumab (50 mg or 100 mg) maintained clinical response through week 54 in patients who responded to induction therapy with golimumab and had moderate-to-severe active ulcerative colitis; patients who received 100 mg Golimumab had clinical remission and mucosal healing at weeks 30 and 54. Expand
Randomized clinical trial: Atorvastatin versus placebo in patients with acute exacerbation of mild to moderate ulcerative colitis
TLDR
Atorvastatin therapy in acute exacerbation of UC may not be associated with beneficial effects and Paradoxical increase in disease activity may be seen in some patients, but these findings need to be substantiated in larger studies. Expand
Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis.
TLDR
Treatment with subcutaneous golimumab induces clinical response, remission, and mucosal healing, and increases quality of life in larger percentages of patients with active UC than placebo. Expand
Vitamin D as a therapy for colitis: a systematic review.
TLDR
Although there is some evidence that supplemental vitamin D, as an adjunctive treatment, may help in controlling colitis, this evidence is not enough to justify using vitamin D in treating inflammatory bowel disease (IBD). Expand
Long-term Clinical Experience with Vedolizumab in Patients with Inflammatory Bowel Disease
TLDR
Vedolizumab every 8 weeks for up to 78 weeks had an adverse event profile similar to that previously observed and mean disease activity indices improved with all 3 doses investigated. Expand
A pharmacokinetic and clinical assessment of tofacitinib for the treatment of rheumatoid arthritis
TLDR
Tofacitinib monotherapy, or in combination with traditional DMARDs, has demonstrated its efficacy while having an acceptable safety profile in RA patients who have responded inadequately to current DMARDS, including TNF antagonists. Expand
Anti-CD3 antibody visilizumab is not effective in patients with intravenous corticosteroid-refractory ulcerative colitis
TLDR
Visilizumab at a dose of 5 μg/kg for two consecutive days was not effective for severe, corticosteroid-refractory UC and was associated with increased cardiac and vascular adverse events. Expand
Current approaches to the management of new-onset ulcerative colitis
TLDR
The authors provide a comprehensive evidence-based approach to current treatment options for new-onset UC with discussion of long-term therapeutic efficacy and safety, patient-centered perspectives including quality of life and medication compliance, and future directions in related inflammatory bowel disease care. Expand
Randomised placebo-controlled trial of rituximab (anti-CD20) in active ulcerative colitis
TLDR
Rituximab has no significant effect on inducing remission in moderately active UC not responding to oral steroids, and is well tolerated in UC. Expand
...
1
2
3
4
5
...